Mechanisms of Cancer Progression and Immune Evasion

Annika Karthik

One of the hallmarks of cancer is the alteration of normal cell signaling pathways that regulate processes such as growth, survival, and cell death. Dysregulation of growth factors is a prominent feature in many cancers. Cancer cells can produce excessive amounts of growth factors or have mutations in their receptors, making them hypersensitive to these signals.

Overexpression and Mutations in Growth Factor Receptors

For example, the epidermal growth factor receptor (EGFR) is often overexpressed or mutated in various cancers (i.e. colorectal cancer, breast cancer, pancreatic cancer), leading to constitutive activation of downstream signaling pathways that drive uncontrolled cell proliferation. This allows cancer cells to bypass normal regulatory signals that would typically limit cell division. In addition to dysregulated growth factor signaling, many cancer cells evade apoptosis, or programmed cell death, which is a vital defense mechanism against the accumulation of damaged or abnormal cells. Tumor cells often overexpress anti-apoptotic proteins, such as Bcl-2, or impair pro-apoptotic signaling pathways, such as those involving p53. These alterations allow cancer cells to survive in conditions that would normally induce cell death, contributing to tumor progression and resistance to therapies.



Evasion of Apoptosis

In addition to apoptosis evasion, the activation of oncogenes further drives the unchecked growth of cancer cells. Oncogenes are mutated forms of normal proto-oncogenes that are typically involved in regulating cell growth and differentiation.



In cancer, mutations can lead to the constitutive activation of these genes, overriding normal cell cycle controls and promoting unchecked cell division. For instance, mutations in the RAS family of genes are common in many cancers and result in the continuous activation of downstream signaling pathways such as the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase (MAPK/ERK) pathway (shown to the left), which drives tumor cell proliferation. In parallel, mutations in tumor suppressor genes, such as p53, remove critical

checkpoints in the cell cycle. Tumor suppressor genes normally function to halt cell division in the presence of DNA damage and to promote apoptosis in damaged cells. When these genes are inactivated or deleted, the cell cycle is no longer properly regulated, leading to genomic instability and an increased risk of further mutations that promote cancer progression.

Activation of Oncogenes and Inactivation of Tumor Suppressors

The ability of cancer cells to evade the immune system is another central feature of tumor biology. One of the most well-known strategies employed by cancer cells for immune system evasion is the modulation of immune checkpoints. For example, tumor cells can express the ligand PD-L1, which binds to the PD-1 receptor on T-cells and inhibits their activation. This prevents T-cells from attacking tumor cells, thereby allowing the cancer to persist.

Advances in Immunotherapy

Recent advances in immunotherapy, particularly the use of checkpoint inhibitors targeting the PD-1/PD-L1 interaction, have shown remarkable promise in cancer treatment. The PD-1/PD-L1 pathway normally acts as an immune checkpoint, preventing T-cells from attacking normal tissues to avoid autoimmunity. However, tumors can exploit this pathway by expressing PD-L1, effectively suppressing immune responses and allowing tumor growth. By blocking this interaction, checkpoint inhibitors restore immune function, enabling T-cells to recognize and attack cancer cells more effectively. This approach has demonstrated significant success in treating cancers like melanoma, non-small cell lung cancer, and bladder cancer, providing patients with longer-lasting responses and improved survival rates. As research advances, checkpoint inhibitors are becoming an essential component of cancer therapy, offering a more targeted and effective treatment strategy.

Immune Evasion via Immune Checkpoints

In addition to immune checkpoint modulation, tumors can release various immunosuppressive factors that dampen the immune response. Cytokines such as transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10) are often secreted by tumor cells to suppress T-cell activation and promote the development of immune tolerance. These factors help create an immunosuppressive environment within the tumor microenvironment



(TME), allowing the cancer cells to grow and evade immune detection. Furthermore, many tumors downregulate the expression of major histocompatibility complex (MHC) molecules, which are essential for presenting tumor antigens to immune cells. This reduction in MHC molecule expression makes it harder for the immune system to recognize and respond to tumor cells.

Immunosuppressive Cytokines and MHC Downregulation

Another mechanism by which tumors evade immune surveillance is through the induction of regulatory T cells (Tregs). Tregs are a subset of immune cells that normally function to maintain immune tolerance and prevent autoimmunity. However, tumors can promote the expansion and recruitment of Tregs to the tumor site, where they suppress the activity of effector T cells that would otherwise attack the tumor. By increasing the number of Tregs, tumors can further suppress immune responses and create a more favorable environment for tumor survival.

Induction of Regulatory T Cells (Tregs)

The TME plays a critical role in cancer progression by influencing both the biology of the tumor and the surrounding immune response. In many cancers, the TME is characterized by chronic inflammation, which can contribute to tumor progression and metastasis. Inflammatory cells such as macrophages and neutrophils are often recruited to the tumor site, where they release cytokines and growth factors that promote tumor cell proliferation, angiogenesis (the formation of new blood vessels), and metastasis. Chronic inflammation can also cause DNA damage, increasing the likelihood of mutations that drive cancer progression. Additionally, inflammatory mediators such as interleukins (e.g., IL-6), which regulate immune responses and inflammation, and prostaglandins, which mediate pain, fever, and immune reactions, can enhance tumor cell survival and create a microenvironment conducive to tumor growth.

Role of Chronic Inflammation in Tumor Progression

Another way cancer evades the immune system is the alteration of the extracellular matrix (ECM), which provides structural support to tissues and regulates cell behavior. In cancer, the ECM is often remodeled to facilitate tumor invasion and metastasis. Tumor cells can secrete enzymes called matrix metalloproteinases (MMPs) that degrade the ECM, allowing the cancer cells to invade surrounding tissues and spread to distant organs. The ECM can also influence the behavior of immune cells in the TME by acting as a physical barrier, suppressing immune infiltration, and promoting the activation of regulatory T-cells and immunosuppressive macrophages. This contributes to immune evasion and tumor growth. In some cases, the altered ECM can even support the formation of new blood vessels, providing tumors with the nutrients and oxygen necessary for continued growth.

ECM Remodeling and Tumor Invasion

Cancer cells also undergo metabolic reprogramming to support their rapid proliferation. A well-known example of this is the Warburg effect, in which tumor cells preferentially use glycolysis for energy production even in the presence of oxygen. This metabolic shift allows cancer cells to generate the necessary intermediates for cell growth while also evading immune detection. The increased production of lactate from glycolysis lowers the pH of the tumor microenvironment, creating an acidic environment that can impair the function of immune cells. This further promotes immune evasion and allows cancer cells to thrive despite the presence of an immune system that would normally target them.



Conclusion

Cancer is driven by a complex array of mechanisms, including genetic mutations, immune evasion, and alterations to the tumor microenvironment. While much progress has been made in understanding these processes, many aspects remain unclear. Researchers are actively exploring the role of the tumor microenvironment, particularly how immune cells interact with cancer cells and contribute to immune resistance. The development of immunotherapies, such as checkpoint inhibitors, has shown promise, but challenges like tumor heterogeneity and immune resistance still hinder progress. Scientists are also investigating metabolic reprogramming in cancer cells, aiming to exploit the unique metabolic demands of tumors for therapeutic advantage. Moving forward, integrating personalized approaches that consider both the genetic landscape of tumors and their microenvironment will be crucial for developing more effective treatments. The continued exploration of novel pathways and technologies, such as CRISPR-based gene editing and artificial intelligence-driven drug discovery, holds great potential for advancing cancer treatment and improving patient outcomes.